Lawmakers urge USPTO to curb IPR denials under Fintiv
21-09-2021
Intel backs Mylan's anti-Fintiv SCOTUS stance
16-09-2021
Mylan asks SCOTUS to end NHK-Fintiv rule
16-08-2021
FTC orders Mylan to divest two generics
09-09-2016
Bill Perry / Shutterstock.com
Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review (IPR) petitions that have been denied due to the NHK-Fintiv rule.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
NHK-Fintiv, Apple, Verizon, Comcast, Mylan Pharmaceuticals, inter partes review, US Supreme Court, US Court of Appeals for the Federal Circuit, patents
